Christopher Kelsey

Christopher Kelsey

Auto-generated profile, based on publicly available information

Christopher Kelsey

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2009 in Cancer
Verified
Journal Article
Open access
PDF file
CKChris R. Kelsey
Chris R. Kelsey
LMLawrence B. Marks
Lawrence B. Marks
DHDonna Hollis
Donna Hollis
JHJessica L. Hubbs
Jessica L. Hubbs
NRNeal E. Ready
Neal E. Ready
JBJessamy A. Boyd
Jessamy A. Boyd
BACKGROUND: The objective of the current study was to evaluate the actuarial risk of local failure (LF) after surgery for stage I to II nonsmall cell lung cancer (NSCLC) and assess surgical and pathologic factors affecting this risk.METHODS: The records, including pertinent radiologic studies, of all patients who underwent surgery for T1 to T2, N0 to N1 NSCLC at Duke University between 1995 and 2005 were reviewed. Risks of disease recurrence were estimated using the Kaplan‐Meier method. A multivariate Cox regression analysis assessed factors associated with LF in the entire cohort and a subgroup undergoing optimal surgery for stage IB to II disease.RESULTS: For all 975 consecutive patients, the 5‐year actuarial risk of local and/or distant disease recurrence was 36%. First sites of failure were local only (25%), local and distant (29%), and distant only (46%). The 5‐year actuarial risk of LF was 23%. On multivariate analysis, squamous/large cell histology (hazards ratio [HR], 1.98), stage > IA (HR, 2.02), and sublobar resections (HR, 1.99) were found to be independently associated with a higher risk of LF. For the subset of patients (n = 445) undergoing at least a lobectomy with negative surgical margins and currently considered for adjuvant chemotherapy (stage IB‐II disease), the 5‐year actuarial risk of LF was 27%. Within this subgroup, squamous/large cell histology (HR, 2.5) and lymphovascular space invasion (HR, 1.74) were associated with a higher risk of LF. The 5‐year rate of LF was 13%, 32%, and 47%, respectively, with 0, 1, or 2 risk factors.CONCLUSIONS: Greater than half of disease recurrences after surgery for early stage NSCLC involved local sites. Pathologic factors may help to distinguish those patients at highest risk. Cancer 2009. © 2009 American Cancer Society.

19 December 2017 in Cancer
Verified
Journal Article
Closed access
PDF file
DTDaniel J. Tandberg
Daniel J. Tandberg
BTBetty C. Tong
Betty C. Tong
BABradley G. Ackerson
Bradley G. Ackerson
CKChris R. Kelsey
Chris R. Kelsey

13 July 2010 in Cancer
Verified
Journal Article
Open access
PDF file
JHJessica L. Hubbs
Jessica L. Hubbs
JBJessamy A. Boyd
Jessamy A. Boyd
DHDonna Hollis
Donna Hollis
JCJunzo P. Chino
Junzo P. Chino
MSMert Saynak
Mert Saynak
CKChris R. Kelsey
Chris R. Kelsey
BACKGROUND: The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%‐50%. The risk for patients with early stage disease is less defined. The authors sought to investigate this further and to study potential risk factors.METHODS: The records of all patients who underwent surgery for T1‐T2 N0‐N1 NSCLC at Duke University between the years 1995 and 2005 were reviewed. The cumulative incidence of brain metastases and distant metastases was estimated by using the Kaplan‐Meier method. A multivariate analysis assessed factors associated with the development of brain metastases.RESULTS: Of 975 consecutive patients, 85% were stage I, and 15% were stage II. Adjuvant chemotherapy was given to 7%. The 5‐year actuarial risk of developing brain metastases and distant metastases was 10%(95% confidence interval [CI], 8‐13) and 34%(95% CI, 30‐39), respectively. Of patients developing brain metastases, the brain was the sole site of failure in 43%. On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases.CONCLUSIONS: In this large series of patients treated surgically for early stage NSCLC, the 5‐year actuarial risk of developing brain metastases was 10%. A better understanding of predictive factors and biological susceptibility is needed to identify the subset of patients with early stage NSCLC who are at particularly high risk. Cancer 2010. © 2010 American Cancer Society.

1 March 1999 in Molecular Biology and Evolution
Verified
Journal Article
Open access
PDF file
Keith A. CrandallKeith A. Crandall
Keith A. Crandall
CKC. R. Kelsey
C. R. Kelsey
HIH. Imamichi
H. Imamichi
HLH. C. Lane
H. C. Lane
NSN. P. Salzman
N. P. Salzman
Parallel or convergent evolution at the molecular level has been difficult to demonstrate especially when rigorous statistical criteria are applied. We present sequence data from the protease gene from eight patients infected with the human immunodeficiency virus (HIV-1). These patients have been on multiple drug therapies for at least 2 years. We present sequence data from two timepoints: time zero--the initiation of drug therapy--and a subsequent timepoint between 59 and 104 weeks after the initiation of drug therapy. In addition to the sequence data, we present viral load data from both initial and final timepoints. Our phylogenetic analyses indicate significant evolution of virus from initial to final time points, even in three of eight patients who show low viral loads. Of the five patients who escaped drug therapy, identical amino acid replacements were seen in all five patients at two different codon positions, an indication of parallel evolution. We also measured genetic diversity for these patients and found no correlation between genetic diversity and viral load. Finally, we calculated the nonsynonymous and synonymous substitution rates and showed that the ratio of nonsynonymous to synonymous substitution compared to the value of one may be a poor indicator of natural selection.

4 September 2014 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
AZAndrew D. Zelenetz
Andrew D. Zelenetz
LGLeo I. Gordon
Leo I. Gordon
WWWilliam G. Wierda
William G. Wierda
JAJeremy S. Abramson
Jeremy S. Abramson
RARanjana H. Advani
Ranjana H. Advani
HSHema Sundar
Hema Sundar
Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

1 February 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
JBJessamy A. Boyd
Jessamy A. Boyd
JHJessica L. Hubbs
Jessica L. Hubbs
DKDong W. Kim
Dong W. Kim
DHDonna Hollis
Donna Hollis
LMLawrence B. Marks
Lawrence B. Marks
CKChris R. Kelsey
Chris R. Kelsey
Introduction Most adjuvant lung cancer trials only report first sites of failure. The relative timing of local (i.e., local/regional) versus distant recurrence after surgery could potentially affect reported rates of local failure. We assessed this phenomenon in a large group of patients undergoing surgery for early-stage lung cancer. Methods This institutional review board-approved retrospective study identified all patients who underwent surgery at Duke University Medical Center for pathologic stages I to II non-small cell lung cancer between 1995 and 2005. Medical records and pertinent radiographs were reviewed to assess for local and distant sites of recurrence. Both first and subsequent failures were examined. The time interval between surgery and date of local and/or distant failure was compared using the Mann-Whitney U test. Results Of 975 patients undergoing surgery, 250 patients developed recurrent disease (43 local only, 110 distant only, and 97 both). The median time from surgery to local failure was 13.9 months (range, 1–79). The median time to distant failure was 12.5 months (range, 1–79 months). These were not significantly different (p = 0.34). Among 97 patients who experienced both local and distant failure, 72 (74%) failed at both sites simultaneously, 19 (20%) failed at local sites first, and 6 (6%) failed at distant sites first. Conclusions The time interval from surgery to either local or distant failure is not significantly different. Patterns of failure analyses in which only first sites of failure are scored will underestimate the frequency of local recurrence. Nevertheless, the magnitude of this error is expected to be small.